Document is current
Any future updates will be listed below
-
Authors
Leger, Adrien https://orcid.org/0000-0001-8772-6776
Amaral, Paulo P.
Pandolfini, Luca https://orcid.org/0000-0003-1444-8167
Capitanchik, Charlotte
Capraro, Federica https://orcid.org/0000-0001-8974-4951
Miano, Valentina https://orcid.org/0000-0002-0260-5885
Migliori, Valentina
Toolan-Kerr, Patrick
Sideri, Theodora
Enright, Anton J.
Tzelepis, Konstantinos https://orcid.org/0000-0002-4865-7648
van Werven, Folkert J. https://orcid.org/0000-0002-6685-2084
Luscombe, Nicholas M. https://orcid.org/0000-0001-5293-4778
Barbieri, Isaia https://orcid.org/0000-0003-3035-8970
Ule, Jernej https://orcid.org/0000-0002-2452-4277
Fitzgerald, Tomas https://orcid.org/0000-0002-2370-8496
Birney, Ewan https://orcid.org/0000-0001-8314-8497
Leonardi, Tommaso https://orcid.org/0000-0002-4449-1863
Kouzarides, Tony https://orcid.org/0000-0002-8918-4162
-
Funding
Funding for this research was provided by:
Cancer Research UK (FC001203, RG72100, C6946/A24843)
Wellcome Trust (FC001203, WT203144)
- License Information
-
More Information
Article History
Received: 31 August 2021
Accepted: 9 November 2021
First Online: 10 December 2021
Competing interests
: E.B. is a paid consultant and shareholder of O.N.T. T.K. is a co-founder of Abcam and a co-founder of STORM Therapeutics Limited. P.P.A. was a Research Scientist and paid Consultant at STORM Therapeutics Limited. T.L. is a paid consultant of STORM Therapeutics Limited and received reimbursement of registration fees from ONT to speak at an event. A.L. received free consumables from ONT during the project and is currently an employee of ONT. The remaining authors declare no competing interests.
